In the not too distant past, malaria could be found all around the globe – from China to Australia, Russia to South Africa and Canada to Argentina. Today, thanks to significant public health efforts over recent years, the malaria map has successfully been reduced to a fraction of its former self. Nevertheless, the disease continues to plague many countries in Asia, Africa and Latin America.

In Latin America, the vast majority of the continent’s cases occur in Brazil. The burden is particularly high in Amazonia, where continued development in construction, mining and farming enables the disease to spread rapidly.

The reduction of the burden of malaria is one of the main objectives of the Millennium Development Goals (MDGs) and one the thousands of work-days and school-days continue to be lost every year. Studies have also shown that malaria can have adverse effects on children’s cognitive ability. In the most severe cases, it is not just time, capability and potential that is lost, but lives.

As a consequence of this loss of life and productivity, this tiny parasite traps families and communities in an endless cycle of poverty – hindering social and economic development.

Better anti-relapse drugs would make malaria elimination in Brazil a real possibility.

Prof. Marcus Lacerda, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil

In the not too distant past, malaria could be found all around the globe – from China to Australia, Russia to South Africa and Canada to Argentina. Today, thanks to significant public health efforts over recent years, the malaria map has successfully been reduced to a fraction of its former self. Nevertheless, the disease continues to plague many countries in Asia, Africa and Latin America.

In Latin America, the vast majority of the continent’s cases occur in Brazil. The burden is particularly high in Amazonia, where continued development in construction, mining and farming enables the disease to spread rapidly.

The reduction of the burden of malaria is one of the main objectives of the Millennium Development Goals (MDGs) and one the thousands of work-days and school-days continue to be lost every year. Studies have also shown that malaria can have adverse effects on children’s cognitive ability. In the most severe cases, it is not just time, capability and potential that is lost, but lives.

As a consequence of this loss of life and productivity, this tiny parasite traps families and communities in an endless cycle of poverty – hindering social and economic development.

Better anti-relapse drugs would make malaria elimination in Brazil a real possibility.

Prof. Marcus Lacerda, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil

In the not too distant past, malaria could be found all around the globe – from China to Australia, Russia to South Africa and Canada to Argentina. Today, thanks to significant public health efforts over recent years, the malaria map has successfully been reduced to a fraction of its former self. Nevertheless, the disease continues to plague many countries in Asia, Africa and Latin America.

In Latin America, the vast majority of the continent’s cases occur in Brazil. The burden is particularly high in Amazonia, where continued development in construction, mining and farming enables the disease to spread rapidly.

The reduction of the burden of malaria is one of the main objectives of the Millennium Development Goals (MDGs) and one the thousands of work-days and school-days continue to be lost every year. Studies have also shown that malaria can have adverse effects on children’s cognitive ability. In the most severe cases, it is not just time, capability and potential that is lost, but lives.

As a consequence of this loss of life and productivity, this tiny parasite traps families and communities in an endless cycle of poverty – hindering social and economic development.

Better anti-relapse drugs would make malaria elimination in Brazil a real possibility.

Prof. Marcus Lacerda, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil

In the not too distant past, malaria could be found all around the globe – from China to Australia, Russia to South Africa and Canada to Argentina. Today, thanks to significant public health efforts over recent years, the malaria map has successfully been reduced to a fraction of its former self. Nevertheless, the disease continues to plague many countries in Asia, Africa and Latin America.

In Latin America, the vast majority of the continent’s cases occur in Brazil. The burden is particularly high in Amazonia, where continued development in construction, mining and farming enables the disease to spread rapidly.

The reduction of the burden of malaria is one of the main objectives of the Millennium Development Goals (MDGs) and one the thousands of work-days and school-days continue to be lost every year. Studies have also shown that malaria can have adverse effects on children’s cognitive ability. In the most severe cases, it is not just time, capability and potential that is lost, but lives.

As a consequence of this loss of life and productivity, this tiny parasite traps families and communities in an endless cycle of poverty – hindering social and economic development.

Better anti-relapse drugs would make malaria elimination in Brazil a real possibility.

Prof. Marcus Lacerda, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil

In the not too distant past, malaria could be found all around the globe – from China to Australia, Russia to South Africa and Canada to Argentina. Today, thanks to significant public health efforts over recent years, the malaria map has successfully been reduced to a fraction of its former self. Nevertheless, the disease continues to plague many countries in Asia, Africa and Latin America.

In Latin America, the vast majority of the continent’s cases occur in Brazil. The burden is particularly high in Amazonia, where continued development in construction, mining and farming enables the disease to spread rapidly.

The reduction of the burden of malaria is one of the main objectives of the Millennium Development Goals (MDGs) and one the thousands of work-days and school-days continue to be lost every year. Studies have also shown that malaria can have adverse effects on children’s cognitive ability. In the most severe cases, it is not just time, capability and potential that is lost, but lives.

As a consequence of this loss of life and productivity, this tiny parasite traps families and communities in an endless cycle of poverty – hindering social and economic development.

Better anti-relapse drugs would make malaria elimination in Brazil a real possibility.

Prof. Marcus Lacerda, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil

In the not too distant past, malaria could be found all around the globe – from China to Australia, Russia to South Africa and Canada to Argentina. Today, thanks to significant public health efforts over recent years, the malaria map has successfully been reduced to a fraction of its former self. Nevertheless, the disease continues to plague many countries in Asia, Africa and Latin America.

In Latin America, the vast majority of the continent’s cases occur in Brazil. The burden is particularly high in Amazonia, where continued development in construction, mining and farming enables the disease to spread rapidly.

The reduction of the burden of malaria is one of the main objectives of the Millennium Development Goals (MDGs) and one the thousands of work-days and school-days continue to be lost every year. Studies have also shown that malaria can have adverse effects on children’s cognitive ability. In the most severe cases, it is not just time, capability and potential that is lost, but lives.

As a consequence of this loss of life and productivity, this tiny parasite traps families and communities in an endless cycle of poverty – hindering social and economic development.

Better anti-relapse drugs would make malaria elimination in Brazil a real possibility.

Prof. Marcus Lacerda, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil

In the not too distant past, malaria could be found all around the globe – from China to Australia, Russia to South Africa and Canada to Argentina. Today, thanks to significant public health efforts over recent years, the malaria map has successfully been reduced to a fraction of its former self. Nevertheless, the disease continues to plague many countries in Asia, Africa and Latin America.

In Latin America, the vast majority of the continent’s cases occur in Brazil. The burden is particularly high in Amazonia, where continued development in construction, mining and farming enables the disease to spread rapidly.

The reduction of the burden of malaria is one of the main objectives of the Millennium Development Goals (MDGs) and one the thousands of work-days and school-days continue to be lost every year. Studies have also shown that malaria can have adverse effects on children’s cognitive ability. In the most severe cases, it is not just time, capability and potential that is lost, but lives.

As a consequence of this loss of life and productivity, this tiny parasite traps families and communities in an endless cycle of poverty – hindering social and economic development.

Better anti-relapse drugs would make malaria elimination in Brazil a real possibility.

Prof. Marcus Lacerda, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil

In the not too distant past, malaria could be found all around the globe – from China to Australia, Russia to South Africa and Canada to Argentina. Today, thanks to significant public health efforts over recent years, the malaria map has successfully been reduced to a fraction of its former self. Nevertheless, the disease continues to plague many countries in Asia, Africa and Latin America.

In Latin America, the vast majority of the continent’s cases occur in Brazil. The burden is particularly high in Amazonia, where continued development in construction, mining and farming enables the disease to spread rapidly.

The reduction of the burden of malaria is one of the main objectives of the Millennium Development Goals (MDGs) and one the thousands of work-days and school-days continue to be lost every year. Studies have also shown that malaria can have adverse effects on children’s cognitive ability. In the most severe cases, it is not just time, capability and potential that is lost, but lives.

As a consequence of this loss of life and productivity, this tiny parasite traps families and communities in an endless cycle of poverty – hindering social and economic development.
Searching for solutions for and with Brazil

Part of the solution for malaria in Brazil is the development of new medicines to treat relapsing malaria. Together with partners around the world, MMV is working to discover and develop new effective medicines to cure relapsing and uncomplicated malaria, as well as block the transmission of the disease between humans and mosquitoes.

The lead contender to replace primaquine is currently being trialed with partners in Brazil, Peru, Thailand and India. Early studies show this new medicine could be more effective in a single dose than primaquine.\(^\text{10,11}\)

As we continue our work, we look forward to forging new partnerships in Brazil and helping to train and develop the next generation of researchers to defeat malaria.

Partnering with MMV provides...

- The key to an international research network
- Access to antimalarial research data
- Exchange of best practices and methods
- Research capacity development
- The chance to accelerate the R&D for new tools to defeat malaria in Brazil

Defeating malaria will help…

- Alleviate poverty:
  Complete cure of relapsing malaria can help sufferers help themselves out of poverty.
  - Reduce the malaria burden on healthcare: A single-dose radical cure for relapsing malaria could be sufficient to ensure no relapses and no need for further treatment.
  - Boost economic development: More effective medicines will reduce the number of school/work days lost to malaria.

- Help children:
  - Enable the global community to reach Millennium Development Goal 6: Combat HIV/AIDS, malaria and other diseases.

- Help to achieve the “Brazil Without Misery” plan.

Join us in the fight.  
Be part of the solution.

GIVING CAN ACHIEVE TANGIBLE RESULTS

MMV is leading the way to develop and facilitate the delivery of new, affordable medicines that address unmet medical needs for malaria, including relapsing malaria.

The goal is to help vulnerable populations break the cycle of disease and poverty and build a better future for their families and communities.

To date, MMV and partners have brought four new medicines through regulatory or WHO approval towards patients in need.

Investment in MMV can help ensure new medicines advance through clinical trials, receive regulatory approval and reach those who need them most.

- USD 14 million will enable MMV to co-fund a pivotal study for the clinical development of a new anti-relapse medicine to completely cure \(P.\) vivax malaria
- USD 100,000 per year will fund a project to help identify the next generation of anti-relapse drugs

Current solutions are insufficient

A major problem facing efforts to control malaria is the lack of effective tools to treat it. This is especially true for \(P.\) vivax, the species of parasite responsible for 87% of malaria cases in Brazil.\(^\text{1}\) This parasite can lie dormant for weeks, even years, in a patient’s liver, to appear again and again without warning, each relapse leading to the feverish symptoms of malaria.\(^\text{2}\)

Only one medicine is currently available to stop the relapse – primaquine; but the treatment regimen is long, associated with side effects and often not efficacious.

References

5. Pan American Health Organization Malaria Surveillance Indicators: ais.paho.org/phip/viz/malaria_surv_indicators_popup.asp
8. Prof. Marcus Lucard, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Brazil, personal communication, 18 Dec 2012.

Photos: © 2011 Neil Palmer/CIAT for CIFOR used under a Creative Commons license (CC BY-NC-ND 2.0)

For more information and partnership opportunities contact Andrea Lucard at lucarda@mmv.org; +41 79 846 2048